Parkinson's disease protein PARK7 prevents metabolite and protein damage caused by a glycolytic metabolite

40Citations
Citations of this article
62Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cells are continuously exposed to potentially dangerous compounds. Progressive accumulation of damage is suspected to contribute to neurodegenerative diseases and aging, but the molecular identity of the damage remains largely unknown. Here we report that PARK7, an enzyme mutated in hereditary Parkinson's disease, prevents damage of proteins and metabolites caused by a metabolite of glycolysis. We found that the glycolytic metabolite 1,3-bisphosphoglycerate (1,3-BPG) spontaneously forms a novel reactive intermediate that avidly reacts with amino groups. PARK7 acts by destroying this intermediate, thereby preventing the formation of proteins and metabolites with glycerate and phosphoglycerate modifications on amino groups. As a consequence, inactivation of PARK7 (or its orthologs) in human cell lines, mouse brain, and Drosophila melanogaster leads to the accumulation of these damaged compounds, most of which have not been described before. Our work demonstrates that PARK7 function represents a highly conserved strategy to prevent damage in cells that metabolize carbohydrates. This represents a fundamental link between metabolism and a type of cellular damage that might contribute to the development of Parkinson's disease.

Cite

CITATION STYLE

APA

Heremans, I. P., Caligiore, F., Gerin, I., Bury, M., Lutz, M., Graff, J., … Bommer, G. T. (2022). Parkinson’s disease protein PARK7 prevents metabolite and protein damage caused by a glycolytic metabolite. Proceedings of the National Academy of Sciences of the United States of America, 119(4). https://doi.org/10.1073/pnas.2111338119

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free